Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Fernø, Johan ^a,b   Varela, Luis ^c,d   Skrede, Silje ^a,b   Vázquez, María Jesús ^c,d   Nogueiras, Rubén ^c,d   Diéguez, Carlos ^c,d   Vidal Puig, Antonio ^e   Steen, Vidar M ^a,b   López, Miguel ^c,d  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d Instituto de Salud Carlos III   (Spain)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; AGOUTI RELATED PROTEIN; CLOZAPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LEPTIN; MESSENGER RNA; NEUROPEPTIDE; NEUROPEPTIDE Y; OLANZAPINE; PROOPIOMELANOCORTIN; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; AICA RIBONUCLEOTIDE; BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; OREXINS; RIBONUCLEOTIDE; SIGNAL PEPTIDE;

ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARCUATE NUCLEUS; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFECT; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; FEMALE; FOOD INTAKE; HYPERPHAGIA; HYPOTHALAMUS FUNCTION; INSULIN BLOOD LEVEL; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; WEIGHT GAIN; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; ENZYMOLOGY; FEEDING BEHAVIOR; GENE EXPRESSION REGULATION; GENETICS; HYPOTHALAMUS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

AGOUTI; RATTUS;

AGOUTI-RELATED PROTEIN; AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ARCUATE NUCLEUS; BENZODIAZEPINES; CLOZAPINE; FEEDING BEHAVIOR; FEMALE; GENE EXPRESSION REGULATION; HYPERPHAGIA; HYPOTHALAMUS; INJECTIONS, INTRAVENTRICULAR; INSULIN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEPTIN; NEUROPEPTIDE Y; NEUROPEPTIDES; PHOSPHORYLATION; PRO-OPIOMELANOCORTIN; RATS; RATS, SPRAGUE-DAWLEY; RIBONUCLEOTIDES; SIGNAL TRANSDUCTION; WEIGHT GAIN;

EID: 79958694588     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020571     Document Type: Article

References (53)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, et al. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686-1696.
2. American Diabetes Association APAAmerican Association of Clinical EndocrinologistsNorth American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65: 267-272.
3. Colton CW, Manderscheid RW, (2006) Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 3: A42.
4. Weiden PJ, Mackell JA, McDonnell DD, (2004) Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 66: 51-57.
5. Blouin M, Tremblay A, Jalbert ME, Venables H, Bouchard RH, et al. (2008) Adiposity and eating behaviors in patients under second generation antipsychotics. Obesity (Silver Spring) 16: 1780-1787.
6. Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ, (2005) A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 181: 80-89.
7. Pouzet B, Mow T, Kreilgaard M, Velschow S, (2003) Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 75: 133-140.
8. Hartfield AW, Moore NA, Clifton PG, (2003) Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology (Berl) 167: 115-122.
9. Hartfield AW, Moore NA, Clifton PG, (2006) Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats. Neuropsychopharmacology 31: 1938-1945.
10. Nasrallah HA, (2008) Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13: 27-35.
11. Reynolds GP, Kirk SL, (2010) Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Pharmacol Ther 125: 169-179.
12. Carling D, (2004) The AMP-activated protein kinase cascade--a unifying system for energy control. Trends Biochem Sci 29: 18-24.
13. Hu Z, Cha SH, Chohnan S, Lane MD, (2003) Hypothalamic malonyl-CoA as a mediator of feeding behavior. Proc Natl Acad Sci U S A 100: 12624-12629.
14. Kahn BB, Alquier T, Carling D, Hardie DG, (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25.
15. Lage R, Diéguez C, Vidal-Puig A, López M, (2008) AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med 14: 539-549.
16. López M, Lelliott CJ, Vidal-Puig A, (2007) Hypothalamic fatty acid metabolism: a housekeeping pathway that regulates food intake. Bioessays 29: 248-261.
17. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW, (2006) Central nervous system control of food intake and body weight. Nature 443: 289-295.
18. Kirk SL, Cahir M, Reynolds GP, (2006) Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus. J Psychopharmacol 20: 577-579.
19. Huang XF, Deng C, Zavitsanou K, (2006) Neuropeptide Y mRNA expression levels following chronic olanzapine, clozapine and haloperidol administration in rats. Neuropeptides 40: 213-219.
20. Davoodi N, Kalinichev M, Korneev SA, Clifton PG, (2009) Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. Psychopharmacology (Berl) 203: 693-702.
21. Guesdon B, Denis RG, Richard D, (2010) Additive effects of olanzapine and melanin-concentrating hormone agonism on energy balance. Behav Brain Res 207: 14-20.
22. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH, (2007) From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 104: 3456-3459.
23. López M, Lage R, Saha AK, Pérez-Tilve D, Vázquez MJ, et al. (2008) Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab 7: 389-399.
24. López M, Lelliott CJ, Tovar S, Kimber W, Gallego R, et al. (2006) Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA. Diabetes 55: 1327-1336.
25. López M, Varela L, Vázquez MJ, Rodriguez-Cuenca S, Gonzalez CR, et al. (2010) Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 16: 1001-1008.
26. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, et al. (2004) AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428: 569-574.
27. Lane MD, Wolfgang M, Cha SH, Dai Y, (2008) Regulation of food intake and energy expenditure by hypothalamic malonyl-CoA. Int J Obes (Lond) 32 (Suppl 4): S49-54.
28. Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM, (2010) Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci 31: 484-497.
29. Albaugh VL, Henry CR, Bello NT, Hajnal A, Lynch SL, et al. (2006) Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring) 14: 36-51.
30. Cooper GD, Harrold JA, Halford JC, Goudie AJ, (2008) Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 32: 428-436.
31. Goudie AJ, Smith JA, Halford JC, (2002) Characterization of olanzapine-induced weight gain in rats. J Psychopharmacol 16: 291-296.
32. Arjona AA, Zhang SX, Adamson B, Wurtman RJ, (2004) An animal model of antipsychotic-induced weight gain. Behav Brain Res 152: 121-127.
33. Coccurello R, Brina D, Caprioli A, Conti R, Ghirardi O, et al. (2009) 30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice. J Clin Psychopharmacol 29: 576-583.
34. Coccurello R, Caprioli A, Conti R, Ghirardi O, Borsini F, et al. (2008) Olanzapine (LY170053, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo[2,1-b][1,3]benzothiazepine), chronic administration induces weight gain, hyperphagia, and metabolic dysregulation in mice. J Pharmacol Exp Ther 326: 905-911.
35. Coccurello R, Caprioli A, Ghirardi O, Conti R, Ciani B, et al. (2006) Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. Psychopharmacology (Berl) 186: 561-571.
36. Coccurello R, D'Amato FR, Moles A, (2008) Chronic administration of olanzapine affects Behavioral Satiety Sequence and feeding behavior in female mice. Eat Weight Disord 13: e55-60.
37. Fell MJ, Marshall KM, Williams J, Neill JC, (2004) Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J Psychopharmacol 18: 149-155.
38. Minet-Ringuet J, Even PC, Goubern M, Tome D, de Beaurepaire R, (2006) Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite 46: 254-262.
39. Minet-Ringuet J, Even PC, Lacroix M, Tome D, de Beaurepaire R, (2006) A model for antipsychotic-induced obesity in the male rat. Psychopharmacology (Berl) 187: 447-454.
40. Martins PJ, Haas M, Obici S, (2010) Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes 59: 2418-2425.
41. Ferno J, Vik-Mo AO, Jassim G, Havik B, Berge K, et al. (2009) Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology (Berl) 203: 73-84.
42. Jin H, Meyer JM, Mudaliar S, Jeste DV, (2008) Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res 100: 70-85.
43. López M, Seoane LM, Tovar S, García MC, Nogueiras R, et al. (2005) A possible role of neuropeptide Y, agouti-related protein and leptin receptor isoforms in hypothalamic programming by perinatal feeding in the rat. Diabetologia 48: 140-148.
44. López M, Tovar S, Vázquez MJ, Williams LM, Diéguez C, (2007) Peripheral tissue-brain interactions in the regulation of food intake. Proc Nutr Soc 66: 131-155.
45. Vazquez MJ, Gonzalez CR, Varela L, Lage R, Tovar S, et al. (2008) Central resistin regulates hypothalamic and peripheral lipid metabolism in a nutritional-dependent fashion. Endocrinology 149: 4534-4543.
46. Sangiao-Alvarellos S, Varela L, Vazquez MJ, Da Boit K, Saha AK, et al. (2010) Influence of ghrelin and growth hormone deficiency on AMP-activated protein kinase and hypothalamic lipid metabolism. Journal of neuroendocrinology 22: 543-556.
47. Andrews ZB, Liu ZW, Walllingford N, Erion DM, Borok E, et al. (2008) UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. Nature 454: 846-851.
48. Varela L, Vazquez MJ, Cordido F, Nogueiras R, Vidal-Puig A, et al. (2011) Ghrelin and lipid metabolism: key partners in energy balance. Journal of molecular endocrinology 46: R43-63.
49. López M, (2008) The AMPK-malonyl-CoA-CPT1 axis in the control of hypothalamic neuronal function. Cell Metab 8: 176-176.
50. Lage R, Vazquez MJ, Varela L, Saha AK, Vidal-Puig A, et al. (2010) Ghrelin effects on neuropeptides in the rat hypothalamus depend on fatty acid metabolism actions on BSX but not on gender. The FASEB journal: official publication of the Federation of American Societies for Experimental Biology 24: 2670-2679.
51. Cope MB, Nagy TR, Fernandez JR, Geary N, Casey DE, et al. (2005) Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes (Lond) 29: 607-614.
52. Chakravarthy MV, Zhu Y, López M, Yin L, Wozniak DF, et al. (2007) Brain fatty acid synthase activates PPARalpha to maintain energy homeostasis. The Journal of clinical investigation 117: 2539-2552.
53. Paxinos G, (1986) The rat brain in stereotaxic coordinates. Sydney Academic Press.